TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Glaxo Tries a Linux Approach GlaxoSmithKline is applying open-source principles in an effort to help find a drug for malaria, providing to the public the designs behind 13,500 chemical compounds and seeking input from outsiders. online.wsj.com |
Baxter International Q2 2010 Earnings Call Transcript Baxter International (BAX)Q2 2010 Earnings CallJuly 22, 2010 8:30 am ETComplete Story » seekingalpha.com |
Kevin Tang Spots Another Winner: Penwest Sells to Endo ValueHuntr submits:Kevin Tang has done it again.Just a few days ago we wrote an article on Penwest Pharma (PPCO) and the possibility of realizing over-average returns in the near term due to Kevin Tang’s push to wind down the company’s operations so that shareholders could fully realize the OpanaER royalty payments. If that was the case, shareholders would have been able to realize roughly $23 mm of annual royalty payments until at least 2013, which represented a 21% annual return on investment over those three years based on the enterprise value of $111mm at the time the previous article was written.Complete Story » seekingalpha.com |
High-Strength Saline Fails in Brain Therapy A treatment paramedics use for brain injuries was found ineffective, the latest therapy for such traumas to fail. online.wsj.com |
Arena's Weight Loss Drug Battles for Its Life EP Vantage submits:In the end the FDA’s rejection of Arena Pharmaceuticals’ (ARNA) Lorqess weight-loss drug was more damning than predicted. In addition to citing cancer signals debated in a negative advisory committee meeting last month, the announcement of the complete response letter also reveals that the agency questioned whether the drug works at all in non-diabetics (Arena falls through floor with adcom vote, September 17, 2010).It goes without saying the product known generically as lorcaserin is in a battle for its life. News that the FDA has requested data from the Bloom-DM study in type 2 diabetics, due within weeks, suggests that Lorqess still has a possible path forward in obese patients with medical complications, although that road would have many potholes. Whether US partner Eisai (ESALY.PK) would be pleased with additional clinical trials or a smaller indication is not clear, although its chief executive did express continued support for Lorqess.Complete Story » seekingalpha.com |